Adaptive Biotechnologies
The firm is expanding its plans from a Crohn's disease test to a broader GI differential diagnostic and continues to expect to launch its Lyme disease assay by year-end.
GenomeWeb Index Falls Again in March, Led by 29 Percent Decline in Adaptive Biotech Stock
The GenomeWeb Index underperformed the Dow Jones and the Nasdaq, but outperformed the Nasdaq Biotechnology Index last month.
FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test
The test leverages immune repertoire sequencing technology to identify individuals who have had a recent or prior SARS-CoV-2 infection.
Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.
Adaptive Biotechnologies Q4 Revenues Rise 25 Percent
The immune cell sequencing company beat Wall Street estimates on the top line, but missed on the bottom line for both Q4 and full-year 2020.
Nov 11, 2020
Nov 10, 2020
Adaptive Biotechnologies Q3 Revenues Grow 1 Percent
May 13, 2020
May 12, 2020